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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
The primary objective of the review is to assess the effectiveness of intervention components that seek to increase attendance for diabetic
retinopathy screening in people with type 1 and type 2 diabetes.
Secondary objectives:
• To use validated taxonomies of QI intervention strategies and behaviour change techniques (BCTs) to code the description of
interventions in the included studies and determine whether interventions that include particular QI strategies or component BCTs
are more effective in increasing screening attendance;
• To explore heterogeneity in effect size within and between studies to identify potential explanatory factors for variability in effect
size;
• To explore differential effects in subgroups to provide information on how equity of screening attendance could be improved;
• To critically appraise and summarise current evidence on the resource use, costs and cost-effectiveness.
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B A C K G R O U N D
Description of the condition
Diabetic retinopathy is the most common microvascular com-
plication of diabetes mellitus and a leading cause of blindness
amongst the working-age adult population in the Western world
(Sivaprasad 2012). The condition affects approximately a third
of individuals with diabetes (Yau 2012) with a higher prevalence
in people of South Asian, African and Latin American descent,
compared to white populations (Sivaprasad 2012). Risk factors
for the development and progression of diabetic retinopathy in-
clude: duration of diabetes, poor glycaemic control, hypertension
and hyperlipidaemia (Yau 2012). It has been estimated that glob-
ally approximately 93 million individuals may have some form
of diabetic retinopathy, with 28 million suffering from the sight-
threatening end points of the disease (Yau 2012). There is limited
evidence on the economic burden of diabetic retinopathy. One
recent estimate for healthcare costs in Sweden was EUR 106,000
per 100,000 population per year based upon a prevalence of dia-
betes of 4.8% (95% conﬁdence interval 4.7 to 4.9) (Heintz 2010).
These costs exclude cost impacts on those with diabetic retinopa-
thy and their families.
Although effective treatments are available for sight-threatening
diabetic retinopathy in the form of laser photocoagulation (Evans
2014) and more recently the use of anti-vascular endothelial
growth factor inhibitors (Virgili 2014), the success of these in-
terventions is dependent on early detection and timely referral
for treatment. Diabetic retinopathy screening fulﬁls the World
Health Organization (WHO) criteria for a screening programme
(Scanlon 2008): namely, diabetes-associated visual impairment is
an important public health problem; potentially sight-threaten-
ing retinopathy has a recognisable latent stage; a universally ac-
cepted and effective treatment is available; and screening has been
shown to be cost-effective in terms of sight years preserved com-
pared with no screening (Jones 2010). Annual or biennial diabetic
retinopathy screening is recommended in many countries using
a variety of screening modalities including: ophthalmoscopy per-
formed by a number of healthcare professionals (including oph-
thalmologists, optometrists, diabetic physicians) or using standard
retinal photography or digital fundus imaging (American Diabetes
Association 2015; Kristinsson 1995; Scanlon 2008). However, rel-
atively few countries have introduced a national population-based
diabetic retinopathy screening programme and in most parts of
the world screening remains non-systematic.
The reference standard for the detection of diabetic retinopathy
consists of seven standard 35-degree colour photographic ﬁelds
as described by the Early Treatment Diabetic Retinopathy Study
(EDTRS) research group (EDTRS 1991).However this technique
is impractical for widespread retinopathy screening. Although
ophthalmoscopy through dilated pupils has traditionally been the
method of choice for opportunistic screening, the procedure varies
in diagnostic accuracy depending on the particular technique
used (direct or indirect ophthalmoscopy) or the experience of the
healthcare professional performing the test (Hutchinson 2000).
Recent developments in digital retinal photography have facili-
tated rapid acquisition of high-quality fundus images that can be
stored and subsequently graded. Digital imaging combined with
trained graders has been shown to be an effective screening tool to
identify sight-threatening retinopathy (Williams 2004) and is in-
creasingly gaining acceptance for population screening (Kirkizlar
2013; Sharp 2003; Silva 2009; Taylor 2007).
Despite evidence supporting the effectiveness of retinopathy
screening in reducing the risk of sight loss in people with dia-
betes, screening coverage is consistently below recommended lev-
els (Millett 2006; Paz 2006; Saadine 2008). Several factors have
been shown to affect access and attendance for retinopathy screen-
ing including ethnicity, younger age (less than 40 years), a longer
duration of diabetes, and living in areas of high social deprivation
(Byun 2013; Gulliford 2010; Hwang 2015; Kliner 2012).
Description of the intervention
Several interventions speciﬁcally aimed at improving retinopathy
screening, including those targeting patients, health professionals
or the healthcare system have been shown to be effective in im-
proving attendance across a range of retinopathy screening mod-
els (Zhang 2007). Examples of patient-focused interventions in-
clude: (1) educational programmes to increase awareness of dia-
betic retinopathy and promote self management, and (2) the use
of prompts/reminders. Provider-focused interventions include: (1)
clinician education, and (2) audit and performance feedback. Sys-
tem interventions include: (1) team changes; (2) establishing elec-
tronic registration and recall, and (3) the use of telemedicine.
In addition to strategies that speciﬁcally target retinopathy screen-
ing, general quality improvement (QI) implementation strategies
for diabetes care may also be effective in improving screening cov-
erage. A recent systematic review and meta-analysis of trials as-
sessing a number of predeﬁned QI strategies to improve diabetes
care reported that these were associated with a signiﬁcant increase
in retinopathy screening compared to usual care (risk ratio 1.22
(95% conﬁdence interval 1.13 to 1.32)) (Tricco 2012). However,
this review did not include studies where interventions were solely
targeted at patients, and the authors were unable to distinguish
the effectiveness of individual QI components or identify poten-
tial effect modiﬁers. Furthermore, the review did not include an
economic perspective.
How the intervention might work
The majority of studies assessing the effectiveness of interventions
to improve diabetes care (including those delivered speciﬁcally
to improve retinopathy screening) often involve multicomponent
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interventions (i.e. consisting of more than one quality improve-
ment strategy) that attempt to change the behaviour of healthcare
professionals (e.g. advising patients to attend diabetic retinopathy
screening) or patients (e.g. actually attending), or both. As there
is no consistent association between the number of intervention
components and their effectiveness (Grimshaw 2004), the ‘ideal’
number of components in such programmes is unknown. Fur-
thermore, given the complexity of interventions tested to date, it
is not always clear which speciﬁc components are the effective ele-
ments of these interventions (i.e. the ’active ingredients’). Hence,
the content of complex behaviour change interventions has been
referred to as a ’black box’ (Grimshaw 2014). There is evidence
that the more clearly the ’active’ components of a complex in-
tervention are described, the more readily the intervention may
be delivered in an effective, consistent and cost-effective manner
(Michie 2009). Therefore, identiﬁcation of the effective interven-
tions for increasing attendance for diabetic retinopathy screen-
ing ﬁrst requires clarity about intervention content and the func-
tional relationship between components of interventions and the
intended outcome. The Cochrane Effective Practice and Organ-
isation of Care (EPOC) Group have developed a taxonomy that
can be used to classify intervention content in systematic reviews
(EPOC 2002). Although the EPOC taxonomy provides a com-
mon language and a useful summary description of the interven-
tion, the taxonomy may not be sufﬁciently detailed to specify the
components of the intervention clearly (Presseau 2015). A com-
plementary approach is to provide a comprehensive categorisation
of the ingredients of the intervention in terms of the behaviour
change techniques (BCTs) used. BCTs are deﬁned as the ‘observ-
able, replicable and irreducible components of an intervention
that are designed to alter or redirect causal processes regulating
behaviour’ (Michie 2013). Recently, a reliable taxonomy of 93
BCTs has been published (co-developed by team member JF) to
provide a common, consistent terminology (BCT Taxonomy ver-
sion 1 (BCTTv1)), by which the component BCTs in complex
interventions may be identiﬁed and described. Examples of BCT
labels include: ‘goal setting,’ ‘self monitoring,’ ‘providing feedback
on behaviour’ and ‘problem solving’. Review team members (JP,
NI and JG) have successfully demonstrated the feasibility of using
the BCTTv1 within trials of QI interventions for diabetes care
(Presseau 2015).
Why it is important to do this review
Given the value of screening for reducing the risk of sight loss
amongst people with diabetes, it is essential that attendance for
retinopathy screening is maximised as far as available resources al-
low. Wide geographical variation in screening coverage has been
reported, with associated inequalities in outcomes. Given the in-
cremental costs (resource use) and beneﬁts (effects) associated with
interventions to improve attendance for retinopathy screening, it
is important to consider whether such strategies are worthwhile.
By identifying the active components of interventions that in-
crease attendance for screening, this review will contribute to the
identiﬁcation of implementation strategies for early detection of
sight-threatening retinopathy. Furthermore, by exploring the dif-
ferential effects of interventions in particular subgroups the results
may provide clues to help to reduce inequalities in screening at-
tendance and determine the impact of inequity on intervention
effectiveness and efﬁciency. Although there have been a number
of systematic reviews on interventions to optimise adult screening
programmes (Everett 2011; Holden 2010), it is likely that this evi-
dence is not directly transferable to retinopathy screening. Screen-
ing for diabetic retinopathy differs from other forms of screening
in that the target group already has signiﬁcant contact with the
healthcare system due to their underlying diabetes, and screening
has to be life-long (i.e. annual surveillance is necessary).
O B J E C T I V E S
The primary objective of the review is to assess the effectiveness
of intervention components that seek to increase attendance for
diabetic retinopathy screening in people with type 1 and type 2
diabetes.
Secondary objectives:
• To use validated taxonomies of QI intervention strategies
and behaviour change techniques (BCTs) to code the description
of interventions in the included studies and determine whether
interventions that include particular QI strategies or component
BCTs are more effective in increasing screening attendance;
• To explore heterogeneity in effect size within and between
studies to identify potential explanatory factors for variability in
effect size;
• To explore differential effects in subgroups to provide
information on how equity of screening attendance could be
improved;
• To critically appraise and summarise current evidence on
the resource use, costs and cost-effectiveness.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs), both indi-
vidually randomised and cluster-RCTs, conducted in a primary or
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secondary care setting, that were either speciﬁcally designed to im-
prove attendance for diabetic retinopathy screening or were eval-
uating general strategies to improve diabetes care, and where the
impact of the intervention on retinopathy screening attendance
was measured. For economic data we will include full economic
evaluations (cost-effectiveness analyses, cost-utility analyses and
cost-beneﬁt analyses), cost analyses and comparative resource util-
isation studies conducted alongside a RCT.
Types of participants
Participants with type 1 and type 2 diabetes mellitus who are
eligible for screening. Controls/comparators will be those persons
with diabetes who were eligible for screening and who did not
receive the trial intervention or received standard care.
Types of interventions
Interventions will comprise any planned strategy or combination
of strategies to improve attendance for diabetic retinopathy screen-
ing targeted at individuals with diabetes (e.g. reminders, promo-
tion of self management), healthcare professionals (e.g. education,
audit and feedback) or the healthcare system (e.g. electronic reg-
istries, team changes). Interventions will include those speciﬁcally
targeting diabetic retinopathy screening or that were part of a gen-
eral strategy to improve diabetes care.
Types of outcome measures
Primary outcomes
The primary outcome will be one or more visits for diabetic
retinopathy screening within a two-year period following imple-
mentation of the intervention. This could be based on self reports
or health-record audit (hospital, primary care physician or screen-
ing administration system record).
Secondary outcomes
• Ongoing adherence to screening based on attendance for
screening following the initial screening post-intervention;
• Economic outcomes:
i) resources (staff time, equipment, consumables)
required to deliver interventions to increase attendance for
screening
ii) costs of staff used to provide interventions; costs of
treatment and care; cost of primary care; lost wages and lost
productivity (work output)
iii) cost-effectiveness (incremental cost-effectiveness ratios
(ICERs); incremental cost per quality-adjusted life year (QALY);
incremental cost per disability-adjusted life year (DALY);
incremental cost-beneﬁt ratios; net beneﬁts)
Search methods for identification of studies
Electronic searches
We will search the Cochrane Central Register of Controlled Tri-
als (CENTRAL) (which contains the Cochrane Eyes and Vi-
sion group Trials Register) and the NHS Economic Evaluation
Database (NHS EED) on the Cochrane Library (latest issues),
Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-
Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMED-
LINE (January 1946 to present), EMBASE (January 1980 to
present), PsycINFO (1967 to present), the Web of Science Con-
ference Proceedings Citation Index-Science (CPCI-S) (January
1990 to present) and Emerging Sources Citation Index (ESCI)
(January 2015 to present), ProQuest Family Health (January
1987 to present), OpenGrey (January 1980 to present), the IS-
RCTN registry (www.isrctn.com/editAdvancedSearch), Clinical-
Trials.gov (www.clinicaltrials.gov) and the World Health Orga-
nization (WHO) International Clinical Trials Registry Platform
(ICTRP) (www.who.int/ictrp/search/en).Wewill not use any date
or language restrictions in the electronic search for trials.
See: Appendices for details of search strategies for CENTRAL and
NHS EED (Appendix 1), MEDLINE (Appendix 2), EMBASE
(Appendix 3), PsychINFO (Appendix 4), CPCI-S and ESCI (
Appendix 5), ProQuest (Appendix 6), OpenGrey (Appendix 7),
ISRCTN (Appendix 8), ClinicalTrials.gov (Appendix 9) and the
ICTRP (Appendix 10).
Searching other resources
We will handsearch the Diabetes UK and World Diabetes
Congress from 1990 onwards, and will search the reference lists
of included studies to identify any additional relevant studies. In
particular we will search the reference lists of included and ex-
cluded studies in Tricco 2012 to identify further potentially rele-
vant studies. Tricco 2012 has identiﬁed studies which have multi-
ple interventions to improve the quality of care in diabetes. Some
studies in this review include screening for diabetic retinopathy,
one of the outcomes being assessed. However, the information on
screening for diabetic retinopathy is not reported in the abstract
or coded in the MeSH or thesaurus headings, so it is unlikely
that the electronic searches will retrieve these studies. In addition
to searching the reference list of Tricco 2012, we will also iden-
tify further new studies as this review is currently being updated.
The protocol for this review has been republished (Ivers 2014), as
whilst the scope of the review remains the same, the update will
explore the role of innovative meta-analysis in systematic reviews
of complex interventions.
We will also contact experts in the ﬁeld to request information
on any ongoing or unpublished studies that would be relevant for
this review.
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Data collection and analysis
Selection of studies
Two review authors will independently screen the titles and ab-
stracts of studies identiﬁed in the electronic searches. We will seek
full copies of research papers in the case of uncertainty, and will
resolve any differences of opinion between review authors by dis-
cussion. We will document reasons for exclusion at this stage.
Data extraction and management
Two review authors working independently will extract data from
the included studies by using a modiﬁed version of the Cochrane
Effective Practice and Organisation of Care (EPOC) group data
collection form. This template incorporates information on study
design, type and duration of interventions, participants, setting,
methods, outcomes, and results.
For the extraction of data on the sociodemographic characteristics
of participants that are known to be important from an equity
perspective, we will use the PROGRESS (place, race, occupation,
gender, religion, education, socioeconomic status, social status)
framework (O’Neill 2014), and will also record whether any inter-
ventions were aimed at disadvantaged or low- and middle-income
country populations.
We will adapt the data extraction form for economic evaluations
from the format used to produce structured abstracts of full eco-
nomic evaluations for inclusion in theNHS Economic Evaluation
Database.
Two review authors will conduct data extraction, and will resolve
discrepancies between them by discussion.
Coding QI intervention components
We will code extracted intervention descriptions using the taxon-
omy of knowledge translation/quality improvement intervention
strategies used by Tricco 2012, which incorporates 12 QI compo-
nents targeting healthcare systems, clinicians or patients. Two re-
view authors will independently code QI components as ’present’
or ’absent’ for both intervention and control arms. We will resolve
discrepancies in QI intervention coding by discussion and if nec-
essary by the involvement of a third review author.
BCT coding of intervention content
We will also code extracted intervention descriptions into com-
ponent BCTs using an established taxonomy of 93 BCTs (Michie
2013) as a coding framework. We will code BCTs for each in-
tended recipient. We will code each intervention separately, in-
cluding control arms. We will code system-level interventions as
targeting either healthcare provider or patient behaviour, or both,
unless an alternative intervention recipient and their behaviour are
reported (e.g. administrative staff sending reminder letters).
We will code BCTs as ‘present’ or ‘absent’ for each intervention
description. There is substantial evidence that the content of com-
plex behaviour change interventions is often poorly described in
published reports, rendering it more difﬁcult to clearly specify the
content of interventions on this basis alone and increasing the risk
of misclassiﬁcation (Lorencatto 2013). Therefore, in the case of
insufﬁcient information being available to adequately specify the
content of the included interventions, we will supplement this
analysis by contacting the authors of included studies with a re-
quest for additional materials or information that provides further
detail on the content of the intervention (e.g. a trial protocol, let-
ters sent to patients, written or audiovisual materials used for QI
strategy). Initial examinations of papers identiﬁed via the scoping
searches indicate this step is likely to be necessary. We will code
received materials using the taxonomy in the same manner as for
the corresponding published reports.
Two review authors will independently conduct BCT coding, re-
solving discrepancies by discussion and if necessary by the involve-
ment of a third review author.
Coding of resource requirement needed to deliver interventions
The various behaviour change interventions may differ in terms
of the quantity of resources needed to deliver them. However, the
quantity of resources required to deliver the intervention may also
be a determinant of the effectiveness of the intervention. We will
explore whether we can review the description of the interven-
tions (treatment and control) in the included studies and classify
the intensity of resource use on a ﬁve-point Likert scale. These
data might be used in a meta-regression, with sensitivity analy-
sis conducted on alternative methods of including such data in
a meta-analysis (e.g. as binary covariates, as continuous variables,
dichotomised).
Two members of the review team will independently review a
sample of 10 included studies, and will grade the intervention
between 1 (least resource-intensive) to 5 (most resource-intensive),
or 0 (unable to determine), and will record how they graded each
study.Wewill compare the scores fromeach review author, andwill
resolve disagreements by discussion or if necessary by arbitration
from a third review author. We will judge this initial pilot to be a
success if the scores fromnine out of 10 studies arewithin onemark
of each other following discussion between the review authors. If
we consider that we canmake a feasible and reproducible approach
to grading, we will use the notes about how each study is graded to
produce a reproducible description of the resource input associated
with each grade on the Likert scale. We will then use the scale to
extract the resource use required to deliver the interventions in the
other included studies within this review.
Assessment of risk of bias in included studies
Two review authors will independently assess study quality by
using the Cochrane Effective Practice and Organisation of Care
(EPOC) ’Risk of bias’ tool (EPOC 2012). The EPOC criteria for
assessing risk of bias uses nine standard criteria:
• was the allocation sequence adequately generated?
• was the allocation adequately concealed?
• were baseline outcome measurements similar?
• were baseline characteristics similar?
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• were incomplete outcome data adequately addressed?
• was knowledge of the allocated interventions adequately
prevented during the study?
• was the study adequately protected against contamination?
• was the study free from selective outcome reporting?
• was the study free from other risks of bias?
For cluster-RCTs, we will consider particular biases, including: (i)
recruitment bias; (ii) baseline imbalance; (iii) loss of clusters, and
(iv) incorrect analysis; as described in Chapter 16 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
For each domain, two review authors will perform the ’Risk of
bias’ assessment independently and will assign a judgement of ’low
risk’ ’high risk’ or ’unclear risk’ of bias. The review authors will
resolve any discrepancies between them by discussion.
Assessment of the overall methodological quality of included eco-
nomic evaluations based on single, empirical studies will be in-
formed by application of guidelines for authors and peer review-
ers of economic submissions to the BMJ (Drummond 1996) and
ISPOR guidelines for good practice in economic evaluations con-
ducted alongside trials (Ramsey 2015).
Measures of treatment effect
Attendance at screening post-intervention is a dichotomous out-
come. Our measure of intervention effect will be the risk differ-
ence, the actual difference in the observed events between experi-
mental and control interventions.
Unit of analysis issues
To avoid unit-of-analysis errors, we will perform analyses at the
same level as the intervention or control group allocation. For in-
dividual randomised trials the unit of analysis will be the individ-
ual participant. For cluster-randomised trials, we will analyse data
adjusted for clustering. If in cluster-RCTs, outcomes are presented
at patient level (i.e. a unit-of-analysis error) we will use established
methods to adjust for clustering, e.g. by dividing the original sam-
ple size by the design effect, which can be calculated from the aver-
age cluster size and the intra-cluster correlation coefﬁcient (ICC).
Where the ICC is unknown, we will estimate it from similar trials.
Dealing with missing data
We will contact authors of included studies if important data are
not available. If we are not able to obtain these data we will report
the available results and will not impute missing data.
Assessment of heterogeneity
We will assess heterogeneity between trials by visual inspection of
forest plots, and by formal statistical tests of heterogeneity (Chi²
test and the I² statistic). If there is evidence of substantial hetero-
geneity (deﬁned as I² > 50%) and sufﬁcient numbers of trials are
available, we will explore the possible reasons for heterogeneity
using subgroup and random-effects meta-regression analyses.
Assessment of reporting biases
Provided there are sufﬁcient studies (at least 10 for ameta-analysis),
we will examine funnel plots to assess the potential for publication
bias.
Data synthesis
We will conduct meta-analyses in Review Manager 5 (RevMan
2014), using a random-effects model to estimate the pooled risk
difference across studies. We anticipate that a large number of in-
cluded studies will use a cluster-RCT design. We will include data
from RCTs randomised by individual and from cluster-adjusted
RCTs in the same meta-analysis.
In the case of multiple intervention groups, we will combine
groups to create a single pair-wise comparison as recommended
in Chapter 16 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011).
We will summarise characteristics and results of included eco-
nomic evaluations using additional tables, supplemented by a nar-
rative summary that will compare and evaluate methods used and
principal results between studies. We will also tabulate unit cost
data, when available.Wewill report the currency and price year ap-
plicable to measures of costs in each original study alongside mea-
sures of costs, incremental costs and incremental cost-effectiveness,
by study. Where details of currency and price year are available
in original studies, we will convert measures of costs, incremen-
tal costs and cost-effectiveness to 2016 International Dollars us-
ing implicit price deﬂators for gross domestic product (GDP) and
GDP Purchasing Power Parities (CCEMG - EPPI-Centre Cost
Converter).
Subgroup analysis and investigation of heterogeneity
If sufﬁcient studies are available, we will perform the following
subgroup analyses to investigate whether the presence or absence
of particular covariates explain the variability in effect size:
• population subgroups: type 1, type 2 diabetes mellitus,
participant characteristics across PROGRESS categories (race,
gender, education, socioeconomic status)
• component QI strategies/BCTs
• resource requirements to deliver an intervention
We will further investigate associations between screening atten-
dance, QI strategy used and type and number of BCTs and the
impact of baseline screening uptake on effect size by meta-regres-
sion. We will perform meta-regression using the ‘metareg’ macro
available for the Stata statistical package.
6Interventions to increase attendance for diabetic retinopathy screening (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Sensitivity analysis
If data are sufﬁcient, we will conduct a sensitivity analysis to com-
pare studies of high versus low risk of bias (we deﬁne ‘high risk’ as
a study showing a high risk of bias in one or more domains).
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A P P E N D I C E S
Appendix 1. CENTRAL and NHS EED search strategy
#1 MeSH descriptor: [Diabetes Mellitus] explode all trees
#2 MeSH descriptor: [Diabetes Complications] explode all trees
#3 MeSH descriptor: [Diabetic Retinopathy] explode all trees
#4 (diabet* or proliferative or non-proliferative) near/4 retinopath*
#5 diabet* near/3 (eye* or vision or visual* or sight*)
#6 retinopath* near/3 (eye* or vision or visual* or sight*)
#7 DR near/3 (eye* or vision or visual* or sight*)
#8 #1 or #2 or #3 or #4 or #5 or #6 or #7
#9 MeSH descriptor: [Mass Screening] explode all trees
#10 MeSH descriptor: [Vision Tests] explode all trees
#11 MeSH descriptor: [Telemedicine] explode all trees
#12 MeSH descriptor: [Photography] explode all trees
#13 MeSH descriptor: [Ophthalmoscopes] explode all trees
#14 MeSH descriptor: [Ophthalmoscopy] explode all trees
#15 ophthalmoscop* or fundoscop* or funduscop*:ti
#16 (exam* or photo* or imag*) near/3 fundus
#17 photography or retinography
#18 (mydriatic or digital or retina* or fundus or steroscopic) near/3 camera*
#19 (mydriatic or digital or retina* or fundus or steroscopic) near/3 imag*
#20 screen$.tw.
#21 (eye* or retina* or ophthalm*) near/4 exam*
#22 (eye* or vision or retinopathy or ophthalmic) near/4 test*
#23 (eye* or retina* or ophthalm*) near/4 visit*
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#24 MeSH descriptor: [Ofﬁce Visits] this term only
#25 (telemedicine* or telemonitor* or telescreen* or telehealth or teleophthalmology)
#26 #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25
#27 MeSH descriptor: [Quality of Health Care] explode all trees
#28 MeSH descriptor: [Quality of Health Care] this term only
#29 MeSH descriptor: [Quality Improvement] this term only
#30 MeSH descriptor: [Delivery of Health Care] this term only
#31 MeSH descriptor: [Delivery of Health Care, Integrated] this term only
#32 service delivery
#33 decision making
#34 consensus near/3 (process* or discuss)
#35 stakeholder*
#36 MeSH descriptor: [Quality Control] this term only
#37 MeSH descriptor: [Total Quality Management] this term only
#38 MeSH descriptor: [Quality Indicators, Health Care] this term only
#39 MeSH descriptor: [Quality Assurance, Health Care] this term only
#40 quality assurance




#45 (organisation* near/3 cultur*)
#46 MeSH descriptor: [Disease Management] this term only
#47 MeSH descriptor: [Program Evaluation] this term only
#48 (provider* or program*) near/3 (monitor* or evaluate* or modif* or practice)
#49 implement* near/3 (improve* or change* or effort* or issue* or impede* or glossary or tool* or innovation* or outcome* or driv*
or examin* or reexamin* or scale* or strateg* or advis* or expert*)
#50 needs near/3 assess*
#51 (education* or learn*) near/5 (continu* or material* or meeting or collaborat*)
#52 MeSH descriptor: [Medical Audit] explode all trees
#53 audit or feedback or compliance or adherence or training or innovation:ti
#54 guideline* near/3 (clinical or practice or implement* or promot*)
#55 MeSH descriptor: [Health Services Accessibility] explode all trees
#56 outreach near/2 (service$ or visit*)
#57 intervention* near/3 (no or usual or routine or target* or tailor* or mediat*)
#58 usual care
#59 #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44
or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58
#60 MeSH descriptor: [Reminder Systems] explode all trees
#61 remind*
#62 improve* near/3 (attend* or visit* or intervention* or adhere*)
#63 increas* near/3 (attend* or visit* or intervention* or adhere*)
#64 appointment* near/3 (miss* or fail* or remind* or follow up)
#65 MeSH descriptor: [Telephone] this term only
#66 telephone*
#67 MeSH descriptor: [Cell Phones] this term only
#68 MeSH descriptor: [Mobile Applications] this term only
#69 MeSH descriptor: [Remote Consultation] this term only
#70 m-health or e-health or g-health or u-health
#71 phone* near/1 (smart or cell)
#72 smartphone* or cellphone*
#73 hand held device*
#74 mobile near/2 (health or healthcare or phone* or device* or monitor* or comput* or app or apps or application)
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#75 MeSH descriptor: [Internet] this term only
#76 MeSH descriptor: [Social Networking] this term only
#77 email* or text* or message*
#78 letter or mail or mailed or print* or brochure* or newsletter*
#79 #60 or #61 or #62 or #63 or #64 or #65 or #66 or #67 or #68 or #69 or #70 or #71 or #72 or #73 or #74 or #75 or #76 or #77
or #78
#80 MeSH descriptor: [Primary Health Care] this term only
#81 MeSH descriptor: [General Practitioners] this term only
#82 MeSH descriptor: [Physicians, Family] this term only
#83 MeSH descriptor: [Physicians, Primary Care] this term only
#84 MeSH descriptor: [Primary Prevention] this term only
#85 MeSH descriptor: [Preventive Health Services] this term only
#86 MeSH descriptor: [Community Health Services] this term only
#87 MeSH descriptor: [Nurses, Community Health] this term only
#88 MeSH descriptor: [Health Services, Indigenous] this term only
#89 MeSH descriptor: [Rural Health Services] explode all trees
#90 MeSH descriptor: [Mobile Health Units] this term only
#91 Ophthalmologist* or Optometrist* or Optician* or Orthopist* or Refractionists
#92 (Ophthalmic or eye) near/3 (surgeon* or nurse* or technician* or ofﬁcer* or assistant* or staff*)
#93 MeSH descriptor: [Physician’s Practice Patterns] this term only
#94 MeSH descriptor: [Professional Practice] this term only
#95 MeSH descriptor: [Education, Medical, Continuing] this term only
#96 MeSH descriptor: [Nurses] explode all trees
#97 MeSH descriptor: [Specialties, Nursing] this term only
#98 MeSH descriptor: [Nurse’s Role] this term only
#99 MeSH descriptor: [Education, Nursing, Continuing] this term only
#100 nurse or nurses
#101 MeSH descriptor: [Pharmacists] this term only
#102 pharmacist*
#103 (role or roles) near/3 expan*
#104 task* near/3 shift*
#105 MeSH descriptor: [Medical Records Systems, Computerized] explode all trees
#106 MeSH descriptor: [Management Information Systems] this term only
#107 MeSH descriptor: [Database Management Systems] this term only
#108 MeSH descriptor: [Computer Systems] this term only
#109 MeSH descriptor: [Point-of-Care Systems] this term only
#110 MeSH descriptor: [Hospital Information Systems] this term only
#111 (health or healthcare) near/4 (record or management system*)
#112 (decision near/5 support) .ti.
#113 #80 or #81 or #82 or #83 or #84 or #85 or #86 or #87 or #88 or #89 or #90 or #91 or #92 or #93 or #94 or #95 or #96 or #97
or #98 or #99 or #100 or #101 or #102 or #103 or #104 or #105 or #106 or #107 or #108 or #109 or #110 or #111 or #112
#114 MeSH descriptor: [Economics] this term only
#115 MeSH descriptor: [Costs and Cost Analysis] this term only
#116 MeSH descriptor: [Cost Allocation] this term only
#117 MeSH descriptor: [Cost-Beneﬁt Analysis] this term only
#118 MeSH descriptor: [Cost Control] this term only
#119 MeSH descriptor: [Cost Savings] this term only
#120 MeSH descriptor: [Cost of Illness] explode all trees
#121 MeSH descriptor: [Cost Sharing] this term only
#122 MeSH descriptor: [Deductibles and Coinsurance] this term only
#123 MeSH descriptor: [Medical Savings Accounts] this term only
#124 MeSH descriptor: [Health Care Costs] this term only
#125 MeSH descriptor: [Direct Service Costs] this term only
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#126 MeSH descriptor: [Drug Costs] this term only
#127 MeSH descriptor: [Employer Health Costs] this term only
#128 MeSH descriptor: [Hospital Costs] this term only
#129 MeSH descriptor: [Health Expenditures] this term only
#130 MeSH descriptor: [Capital Expenditures] this term only
#131 MeSH descriptor: [Economics, Hospital] explode all trees
#132 MeSH descriptor: [Economics, Medical] explode all trees
#133 MeSH descriptor: [Economics, Nursing] this term only
#134 MeSH descriptor: [Economics, Pharmaceutical] this term only
#135 MeSH descriptor: [Fees and Charges] explode all trees
#136 MeSH descriptor: [Budgets] explode all trees
#137 low* near/2 cost*
#138 high* near/2 cost*
#139 (health care or healthcare) near/2 cost*
#140 ﬁscal or funding or ﬁnancial or ﬁnance
#141 cost near/2 estimate*
#142 cost near/2 variable*
#143 unit near/2 cost*
#144 economic* or pharmacoeconomic* or price* or pricing
#145 MeSH descriptor: [Uncompensated Care] this term only
#146 MeSH descriptor: [Reimbursement Mechanisms] this term only
#147 MeSH descriptor: [Reimbursement, Incentive] this term only
#148 insurance near/3 (health or scheme*)
#149 ﬁnancial or economic or pay or payment or copayment or paid or fee or fees or monetary or money or cash or incentiv* or
disincentiv*
#150 #114 or #115 or #116 or #117 or #118 or #119 or #120 or #121 or #122 or #123 or #124 or #125 or #126 or #127 or #128 or
#129 or #130 or #131 or #132 or #133 or #134 or #135 or #136 or #137 or #138 or #139 or #140 or #141 or #142 or #143 or #144
or #145 or #146 or #147 or #148 or #149
#151 #59 or #79 or #113 or #150
#152 MeSH descriptor: [Patient Acceptance of Health Care] explode all trees
#153 MeSH descriptor: [Attitude to Health] explode all trees
#154 MeSH descriptor: [Health Behavior] explode all trees
#155 barrier* or obstacle* or facilitat* or enable*
#156 uptake or takeup or attend* or accept* or adhere* or attitude* or participat* or facilitat* or utilisat* or utilizat*
#157 complie* or comply or compliance* or noncompliance* or non compliance*
#158 encourag* or discourage* or reluctan* or nonrespon* or non respon* or refuse* or refusal
#159 non-attend* or non attend* or dropout or drop out or apath*
#160 MeSH descriptor: [Health Education] this term only
#161 MeSH descriptor: [Patient Education as Topic] explode all trees
#162 MeSH descriptor: [Health Promotion] explode all trees
#163 health near/2 (promotion* or knowledge or belief*)
#164 educat* near/2 (intervention* or information or material or leaﬂet)
#165 MeSH descriptor: [Socioeconomic Factors] this term only
#166 MeSH descriptor: [Poverty] explode all trees
#167 MeSH descriptor: [Social Class] this term only
#168 MeSH descriptor: [Educational Status] this term only
#169 (school or education*) near/3 (status or level* or attain* or achieve*)
#170 MeSH descriptor: [Employment] this term only
#171 MeSH descriptor: [Healthcare Disparities] this term only
#172 MeSH descriptor: [Health Status Disparities] this term only
#173 MeSH descriptor: [Medically Underserved Area] explode all trees
#174 MeSH descriptor: [Rural Population] this term only
#175 MeSH descriptor: [Urban Population] this term only
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#176 MeSH descriptor: [Ethnic Groups] explode all trees
#177 MeSH descriptor: [Minority Groups] this term only
#178 MeSH descriptor: [Vulnerable Populations] this term only
#179 (health* or social* or racial* or ethnic*) near/5 (inequalit* or inequit* or disparit* or equit* or disadvantage* or depriv*)
#180 disadvant* or marginali* or underserved or under served or impoverish* or minorit* or racial* or ethnic*
#181 #152 or #153 or #154 or #155 or #156 or #157 or #158 or #159 or #160 or #161 or #162 or #163 or #164 or #165 or #166 or
#167 or #168 or #169 or #170 or #171 or #172 or #173 or #174 or #175 or #176 or #177 or #178 or #179 or #180
#182 #151 or #181
#183 #8 and #26 and #182
#184 (ranibizumab or bevacizumab or avastin or aﬂibercept or photocoagulation or coronary or cardiovascular):ti
#185 blood glucose or blood pressure:ti
#186 macula* near/2 (oedema or edema):ti
#187 #184 or #185 or #186
#188 #183 not #187
Appendix 2. MEDLINE (Ovid) search strategy









10. 8 not (8 and 9)
11. 7 not 10
12. exp Randomized Controlled Trials as Topic/
13. 11 or 12
14. exp Diabetes Mellitus/
15. exp Diabetes Complications/
16. exp Diabetic Retinopathy/
17. ((diabet$ or proliferative or non-proliferative) adj4 retinopath$).tw.
18. diabetic retinopathy.kw.
19. (diabet$ adj3 (eye$ or vision or visual$ or sight$)).tw.
20. (retinopath$ adj3 (eye$ or vision or visual$ or sight$)).tw.
21. (DR adj3 (eye$ or vision or visual$ or sight$)).tw.
22. or/14-21
23. exp Mass Screening/





29. (ophthalmoscop$ or fundoscop$ or funduscop$).ti.
30. ((exam$ or photo$ or imag$) adj3 fundus).tw.
31. (photography or retinography).tw.
32. ((mydriatic or digital or retina$ or fundus or steroscopic) adj3 camera).tw.
33. ((mydriatic or digital or retina$ or fundus or steroscopic) adj3 imag$).tw.
34. screen$.tw.
35. ((eye$ or retina$ or ophthalm$) adj4 exam$).tw.
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36. ((eye or vision or retinopathy or ophthalmic) adj4 test$).tw.
37. ((eye$ or retina$ or ophthalm$) adj4 visit$).tw.
38. Ofﬁce Visits/
39. (telemedicine$ or telemonitor$ or telescreen$ or telehealth or teleophthalmology).tw.
40. or/23-39
41. “Quality of Health Care”/
42. Quality Improvement/
43. Delivery of Health Care/
44. Delivery of Health Care, Integrated/
45. service delivery.tw.
46. decision making.tw.
47. (consensus adj3 (process$ or discuss)).tw.
48. stakeholder$.tw.
49. Quality Control/
50. Total Quality Management/
51. Quality Indicators, Health Care/
52. Quality Assurance, Health Care/
53. quality assurance.tw.




58. (organisation$ adj3 cultur$).tw.
59. Disease Management/
60. Program Evaluation/
61. ((provider$ or program$) adj3 (monitor$ or evaluate$ or modif$ or practice)).tw.
62. (implement$ adj3 (improve$ or change$ or effort$ or issue$ or impede$ or glossary or tool$ or innovation$ or outcome$ or driv$
or examin$ or reexamin$ or scale$ or strateg$ or advis$ or expert$)).tw.
63. (need$ adj3 assess$).tw.
64. ((education$ or learn$) adj5 (continu$ or material$ or meeting or collaborat$)).tw.
65. exp Medical audit/
66. (audit or feedback or compliance or adherence or training or innovation).ti.
67. (guideline$ adj3 (clinical or practice or implement$ or promot$)).tw.
68. exp Health Services Accessibility/
69. (outreach adj2 (service$ or visit$)).tw.
70. (intervention$ adj3 (no or usual or routine or target$ or tailor$ or mediat$)).tw.
71. usual care.tw.
72. exp Reminder Systems/
73. remind$.tw.
74. (improve$ adj3 (attend$ or visit$ or intervention$ or adhere$)).tw.
75. (increas$ adj3 (attend$ or visit$ or intervention$ or adhere$)).tw.






82. (m-health or e-health or g-health or u-health).tw.
83. (phone$ adj1 (smart or cell)).tw.
84. (smartphone$ or cellphone$).tw.
85. (hand adj1 held device$).tw.
86. (mobile adj2 (health or healthcare or phone$ or device$ or monitor$ or comput$ or app or apps or application)).tw.
87. Internet/
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88. Social Networking/
89. (email$ or text$ or message$).tw.
90. (letter or mail or mailed or print$ or brochure$ or newsletter$).tw.
91. Primary Health Care/
92. General Practitioners/ or Physicians, Family/ or Physicians, Primary Care/
93. Primary Prevention/
94. Preventive Health Services/
95. Community Health Services/
96. Community Health Nursing/
97. Health Services, Indigenous/
98. Rural Health Services/
99. Mobile Health Units/
100. (Ophthalmologist$ or Optometrist$ or Optician$ or Orthopist$ or Refractionists).tw.
101. ((Ophthalmic or eye) adj3 (surgeon$ or nurse$ or technician$ or ofﬁcer$ or assistant$ or staff$)).tw.
102. Physician’s Practice Patterns/
103. Professional Practice/
104. (professional adj3 (practice or develop$ or educat)).tw.




109. Education, Nursing, Continuing/
110. (nurse or nurses).tw.
111. Pharmacists/
112. pharmacist$.tw.
113. ((role or roles) adj3 expan$).tw.
114. (task$ adj3 shift$).tw.
115. exp Medical Records Systems, Computerized/
116. Management Information Systems/
117. Database Management Systems/
118. Computer Systems/
119. Point-of-Care Systems/
120. Hospital Information Systems/
121. ((health or healthcare) adj4 (record or management system$)).tw.
122. (decision adj5 support).ti.
123. Economics/





129. Cost of illness/
130. Cost sharing/
131. “deductibles and coinsurance”/
132. Medical savings accounts/
133. Health care costs/
134. Direct service costs/
135. Drug costs/




140. Value of life/
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141. exp economics, hospital/
142. exp economics, medical/
143. Economics, nursing/
144. Economics, pharmaceutical/
145. exp “fees and charges”/
146. exp budgets/
147. (low adj cost).mp.
148. (high adj cost).mp.
149. (health?care adj cost$).mp.
150. (ﬁscal or funding or ﬁnancial or ﬁnance).tw.
151. (cost adj estimate$).mp.
152. (cost adj variable).mp.
153. (unit adj cost$).mp.




158. (insurance adj3 (health$ or scheme$)).tw.
159. (ﬁnancial or economic or pay or payment or copayment or paid or fee or fees or monetary or money or cash or incentiv$ or
disincentiv$).tw.
160. or/41-159
161. exp Patient Acceptance of health Care/
162. exp Attitude to Health/
163. exp Health Behavior/
164. (barrier$ or obstacle$ or facilitat$ or enable$).tw.
165. (uptake or takeup or attend$ or accept$ or adhere$ or attitude$ or participat$ or facilitat$ or utilisat$ or utilizat$).tw.
166. (complie$ or comply or compliance$ or noncompliance$ or non compliance$).tw.
167. (encourag$ or discourage$ or reluctan$ or nonrespon$ or non respon$ or refuse$).tw.
168. (non-attend$ or non attend$ or dropout or drop out or apath$).tw.
169. Health Education/
170. exp Patient Education as Topic/
171. exp Health Promotion/
172. exp Counseling/
173. “Attitude of Health Personnel”/
174. (health adj2 (promotion$ or knowledge or belief$)).tw.





180. ((school or education$) adj3 (status or level$ or attain$ or achieve$)).tw.
181. Employment/
182. Healthcare Disparities/
183. Health Status Disparities/
184. exp Medically Underserved Area/
185. Rural Population/
186. Urban Population/
187. exp Ethnic Groups/
188. Minority Groups/
189. Vulnerable Populations/
190. ((health$ or social$ or racial$ or ethnic$) adj5 (inequalit$ or inequit$ or disparit$ or equit$ or disadvantage$ or depriv$)).tw.
191. (disadvant$ or marginali$ or underserved or under served or impoverish$ or minorit$ or racial$ or ethnic$).tw.
192. or/161-191
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193. 160 or 192
194. 13 and 22 and 40 and 193
195. (ranibizumab or bevacizumab or avastin or aﬂibercept or photocoagulation or coronary or cardiovascular).ti.
196. (blood glucose or blood pressure).ti.
197. (macula$ adj2 (oedema or edema)).ti.
198. (cataract or intraocular or glaucoma).ti.
199. macula$ degeneration.ti.
200. nerve ﬁber layer.ti.
201. or/195-200
202. 194 not 201
The search ﬁlter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville (Glanville 2006)
Appendix 3. EMBASE (Ovid) search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. or/1-4
6. (animal or animal experiment).sh.
7. human.sh.
8. 6 and 7
9. 6 not 8
10. 5 not 9
11. exp clinical trial/




16. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
17. exp experimental design/
18. exp crossover procedure/
19. exp control group/
20. exp latin square design/
21. or/11-20
22. 21 not 9
23. 22 not 10
24. exp comparative study/
25. exp evaluation/
26. exp prospective study/
27. (control$ or prospectiv$ or volunteer$).tw.
28. or/24-27
29. 28 not 9
30. 29 not (10 or 22)
31. 10 or 23 or 30
32. “randomized controlled trial (topic)”/
33. 31 or 32
34. exp diabetes mellitus/
35. exp diabetic retinopathy/
36. ((diabet$ or proliferative or non-proliferative) adj4 retinopath$).tw.
37. diabetic retinopathy.kw.
38. (diabet$ adj3 (eye$ or vision or visual$ or sight$)).tw.
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39. (retinopath$ adj3 (eye$ or vision or visual$ or sight$)).tw.
40. (DR adj3 (eye$ or vision or visual$ or sight$)).tw.
41. or/34-40
42. exp Screening/






49. (ophthalmoscop$ or fundoscop$ or funduscop$).ti.
50. ((exam$ or photo$ or imag$) adj3 fundus).tw.
51. (photography or retinography).tw.
52. ((mydriatic or digital or retina$ or fundus or steroscopic) adj3 camera).tw.
53. ((mydriatic or digital or retina$ or fundus or steroscopic) adj3 imag$).tw.
54. screen$.tw.
55. ((eye$ or retina$ or ophthalm$) adj4 exam$).tw.
56. ((eye or vision or retinopathy or ophthalmic) adj4 test$).tw.
57. ((eye$ or retina$ or ophthalm$) adj4 visit$).tw.
58. (telemedicine$ or telemonitor$ or telescreen$ or telehealth or teleophthalmology).tw.
59. or/42-58
60. Health Care Quality/
61. Quality Improvement/
62. Health Care Delivery/
63. Integrated Health Care System/
64. service delivery.tw.
65. decision making.tw.
66. (consensus adj3 (process$ or discuss)).tw.
67. stakeholder$.tw.
68. Quality Control/
69. Total Quality Management/
70. quality assurance.tw.




75. (organisation$ adj3 cultur$).tw.
76. disease management/
77. program evaluation/
78. ((provider$ or program$) adj3 (monitor$ or evaluate$ or modif$ or practice)).tw.
79. (implement$ adj3 (improve$ or change$ or effort$ or issue$ or impede$ or glossary or tool$ or innovation$ or outcome$ or driv$
or examin$ or reexamin$ or scale$ or strateg$ or advis$ or expert$)).tw.
80. (need$ adj3 assess$).tw.
81. ((education$ or learn$) adj5 (continu$ or material$ or meeting or collaborat$)).tw.
82. Medical audit/
83. (audit or feedback or compliance or adherence or training or innovation).ti.
84. (guideline$ adj3 (clinical or practice or implement$ or promot$)).tw.
85. (outreach adj2 (service$ or visit$)).tw.




90. (improve$ adj3 (attend$ or visit$ or intervention$ or adhere$)).tw.
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91. (increas$ adj3 (attend$ or visit$ or intervention$ or adhere$)).tw.






98. (m-health or e-health or g-health or u-health).tw.
99. (phone$ adj1 (smart or cell)).tw.
100. (smartphone$ or cellphone$).tw.
101. (hand adj1 held device$).tw.
102. (mobile adj2 (health or healthcare or phone$ or device$ or monitor$ or comput$ or app or apps or application)).tw.
103. Internet/
104. Social Network/
105. (email$ or text$ or message$).tw.
106. (letter or mail or mailed or print$ or brochure$ or newsletter$).tw.
107. Primary Health Care/
108. General Practitioner/
109. Primary Prevention/
110. Preventive Health Service/
111. Community Care/
112. Community Health Nursing/
113. exp Transcultural Care/
114. Rural Health Care/
115. Ophthalmologist/
116. (Ophthalmologist$ or Optometrist$ or Optician$ or Orthopist$ or Refractionists).tw.









126. (nurse or nurses).tw.
127. pharmacist/
128. pharmacist$.tw.
129. ((role or roles) adj3 expan$).tw.
130. (task$ adj3 shift$).tw.




135. Hospital Information System/
136. ((health or healthcare) adj4 (record or management system$)).tw.
137. (decision adj5 support).ti.
138. cost beneﬁt analysis/
139. cost effectiveness analysis/
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144. health care cost/
145. health care ﬁnancing/
146. health economics/
147. hospital cost/
148. (ﬁscal or ﬁnancial or ﬁnance or funding).tw.
149. cost minimization analysis/
150. (cost adj estimate$).mp.
151. (cost adj variable$).mp.
152. (unit adj cost$).mp.
153. (economic$ or pharmacoeconomic$ or price$ or pricing).tw.
154. exp Reimbursement/
155. (ﬁnancial or economic or pay or payment or copayment or paid or fee or fees or monetary or money or cash or incentiv$ or
disincentiv$).tw.
156. (insurance adj3 (health$ or scheme$)).tw.
157. or/60-156
158. exp Patient Attitude/
159. exp Health Behaviour/
160. (barrier$ or obstacle$ or facilitat$ or enable$).tw.
161. (uptake or takeup or attend$ or accept$ or adhere$ or attitude$ or participat$ or facilitat$ or utilisat$ or utilizat$).tw.
162. (complie$ or comply or compliance$ or noncompliance$ or non compliance$).tw.
163. (encourag$ or discourage$ or reluctan$ or nonrespon$ or non respon$ or refuse$).tw.
164. (non-attend$ or non attend$ or dropout or drop out or apath$).tw.
165. Health Education/
166. exp Patient Education/
167. Diabetes Education/
168. Help Seeking Behavior/
169. Patient Participation/
170. Patient Decision Making/
171. exp Health Promotion/
172. (health adj2 (promotion$ or knowledge or belief$)).tw.






179. ((school or education$) adj3 (status or level$ or attain$ or achieve$)).tw.
180. Employment/











192. ((health$ or social$ or racial$ or ethnic$) adj5 (inequalit$ or inequit$ or disparit$ or equit$ or disadvantage$ or depriv$)).tw.
193. (disadvant$ or marginali$ or underserved or under served or impoverish$ or minorit$ or racial$ or ethnic$).tw.
194. or/158-193
195. 157 or 194
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196. 33 and 41 and 59 and 195
197. (ranibizumab or bevacizumab or avastin or aﬂibercept or photocoagulation or coronary or cardiovascular).ti.
198. (blood glucose or blood pressure).ti.
199. (macula$ adj2 (oedema or edema)).ti.
200. (cataract or intraocular or glaucoma).ti.
201. macula$ degeneration.ti.
202. nerve ﬁber layer.ti.
203. or/197-202
204. 196 not 203
Appendix 4. PsychINFO search strategy
1. exp Treatment Effectiveness Evaluation/






8. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$ or dummy)).tw.
9. (factorial$ or allocat$ or assign$ or volunteer$).tw.
10. (crossover$ or cross over$).tw.
11. (quasi adj (experimental or random$)).tw.
12. (control$ adj3 (trial$ or study or studies or group$)).tw.
13. or/1-12
14. diabetes/
15. ((diabet$ or proliferative or non-proliferative) adj4 retinopath$).tw.
16. (diabet$ adj3 (eye$ or vision or visual$ or sight$)).tw.
17. (retinopath$ adj3 (eye$ or vision or visual$ or sight$)).tw.





23. (ophthalmoscop$ or fundoscop$ or funduscop$).ti.
24. ((exam$ or photo$ or imag$) adj3 fundus).tw.
25. (photography or retinography).tw.
26. ((mydriatic or digital or retina$ or fundus or steroscopic) adj3 camera).tw.
27. ((mydriatic or digital or retina$ or fundus or steroscopic) adj3 imag$).tw.
28. screen$.tw.
29. ((eye$ or retina$ or ophthalm$) adj4 exam$).tw.
30. ((eye or vision or retinopathy or ophthalmic) adj4 test$).tw.
31. ((eye$ or retina$ or ophthalm$) adj4 visit$).tw.
32. (telemedicine$ or telemonitor$ or telescreen$ or telehealth or teleophthalmology).tw.
33. or/20-32
34. 13 and 19 and 33
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Appendix 5. CPCI-S and ESCI search strategy
#11 #10 AND #2 AND #1
#10 #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3
#9 TS = (photography OR retinography OR telemedicine* OR telemonitor* OR telescreen* OR telehealth OR teleophthalmology)
#8 TS = (fundus NEAR/3 exam* OR fundus NEAR/3 photo* OR fundus NEAR/3 imag*)
#7 TS = (imag* NEAR/3 mydriatic OR imag* NEAR/3 digital OR imag* NEAR/3 retina* OR imag* NEAR/3 fundus OR imag*
NEAR/3 steroscopic OR camera NEAR/3 mydriatic OR camera NEAR/3 digital OR camera NEAR/3 retina* OR camera NEAR/3
fundus OR camera NEAR/3 steroscopic)
#6 TI = (ophthalmoscop* OR fundoscop* OR funduscop*)
#5 TS = (visit NEAR/4 eye* OR visit NEAR/4 retina* OR visit NEAR/4 ophthalmic)
#4 TS = (exam* NEAR/4 eye* OR exam* NEAR/4 retina* OR exam* NEAR/4 ophthalmic)
#3 TS = (screen* OR test* NEAR/4 eye OR test* NEAR/4 vision OR test* NEAR/4 retinopathy OR test* NEAR/4 ophthalmic)
#2 TS = (diabetic NEAR/3 retinopath* OR diabetic NEAR/3 eye* OR diabetic NEAR/3 vision OR diabetic NEAR/3 visual* OR
diabetic NEAR/3 sight* OR diabetic NEAR/3 proliferative OR diabetic NEAR/3 “non proliferative”)
#1 TS =(clinical trial* OR research design OR comparative stud* OR evaluation stud* OR controlled trial* OR follow-up stud* OR
prospective stud* OR random* OR placebo* OR single blind* OR double blind*)
Appendix 6. ProQuest Family Health search strategy
ab(diabetic AND(retinopathyOReyeORvisionORvisualOR sight)) ANDab(screenORscreeningOR testORexamORexamination
OR telemedicine ) AND ab(random OR randomly OR randomised OR randomized )
Appendix 7. OpenGrey search strategy
(screen OR test OR exam OR Ophthalmoscopy OR digital OR imaging OR fundus OR telemedicine OR telemonitor OR telescreen
OR telehealth) AND diabetic retinopathy
Appendix 8. ISRCTN search strategy
(screen OR test OR exam OR ophthalmoscopy OR digital OR imaging OR fundus OR telemedicine OR telemonitor OR telescreen
OR telehealth) within Condition: diabetic retinopathy
Appendix 9. ClinicalTrials.gov search strategy
(screen OR test OR exam OR Ophthalmoscopy OR digital OR imaging OR fundus OR telemedicine OR telemonitor OR telescreen
OR telehealth) | Interventional Studies | diabetic retinopathy
Appendix 10. ICTRP search strategy
Condition = diabetic retinopathy AND Intervention = screen OR test OR exam OR Ophthalmoscopy OR digital OR imaging OR
fundus OR telemedicine OR telemonitor OR telescreen OR telehealth
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